FDA Green-Lights New Type 2 Oral Med

4944

On October 17, 2006, the oral medication Januvia (sitagliptin phosphate) was granted approval by the FDA. Januvia is the first diabetes treatment approved in a new class of drugs known as DDP-4 inhibitors that enhances the body’s own ability to lower elevated blood sugar.

Manufactured by Merck and Co., Januvia is indicated for use in addition to diet and exercise to improve blood sugar levels in patients with type 2 diabetes, alone or in combination with two other commonly prescribed oral diabetes medications—metformin or a PPAR (peroxisome proliferator-activated receptor gamma) agonist, when either of these drugs alone, along with diet and exercise, don’t provide adequate blood sugar control.

According to the FDA, “Januvia prolongs the activity of proteins that increase the release of insulin after blood sugar rises, such as after a meal. Januvia does this by blocking an enzyme (dipeptidyl peptidase IV or DPP-IV), which breaks down these proteins, leading to better blood sugar control.

The most common side effects in clinical studies were upper respiratory tract infection, sore throat, and diarrhea.

Source: FDA

Comments

comments

This post authored by
Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.